Gates Foundation commits $280M for research against global TB epidemic
The Bill & Melinda Gates Foundation has announced grants totaling $280.0 million to help fight tuberculosis, an epidemic reported as infecting one third of the global population and which kills nearly two million a year - mostly in the poorest countries. The 11 new grants are intended to speed up R&D on promising vaccines, diagnostic tests and treatments to help reduce the global TB burden, the group said.
Tachi Yamada, president of the Gates Foundation's Global Health Program, said: "TB science has advanced significantly over the past five years, and these grants build on this momentum and the progress that has been made." Dr Yamada added that, "by bringing together a wide range of partners, including scientists from countries heavily affected by TB, we hope to help translate promising ideas into tools that can save millions of lives."
The Foundation's grants focus on three key areas:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze